Search Results
Nov 21, 2025, 07:37 ET The Implementation Playbook: Part 1 of a 5‑Part Series on Hotel PMS Rollouts
discipline or accountability during implementation?In hospitality, we naturally want to go above and beyond for our customers. It's part of our DNA. But there are times when a partner needs to push back.In one case, a property team wasn't engaged or taking responsibility, and we moved forward
More news about: Shiji Group
Nov 21, 2025, 07:30 ET Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
recent years, non-viral DNA template delivery has been combined with engineered nucleases to introduce ssDNA donors. Although effective, this strategy was limited to short DNA templates and therefore mainly supported gene correction. Attempts to use longer double-stranded DNA vectors for gene insertion
More news about: Moligo Technologies
Nov 20, 2025, 13:55 ET CCTV4: Premiere von Chinese Etiquette & Ceremonies: China durch die Linse von Li verstehen
und machen diese Reihe zu einem echten kulturellen Ereignis. Diese große Erkundung der chinesischen Ritualkultur - die Entschlüsselung der Verhaltens-DNA des chinesischen Volkes und die Feier des bleibenden Vermächtnisses von Li - beginnt am Abend des 21. November.
More news about: CCTV4
Nov 20, 2025, 12:01 ET When Sports Go Big, They Go with AstroTurf Corporation
US. Beyond the Speedway Each of these projects shares the same DNA: transforming vision into reality through surfaces engineered for elite performance. The MLB Speedway Classic did not just make
More news about: AstroTurf
Nov 20, 2025, 11:17 ET madSense Launches Agency OS, The First End-to-End AI Ecosystem to see through AdTech's New Walled Gardens
"Transparency and compliance are not optional extras — they are foundational to madSense's DNA," said Gordan Topalovic, Founder and Co-CEO. "With madSense, brands gain an AI partner committed to
More news about: madSense
Nov 20, 2025, 10:01 ET Genomics Market worth $85.09 billion by 2030 with 12.6% CAGR | MarketsandMarkets™
commercializes medical, industrial, and commercial products and services. The company offers genomics products through its subsidiaries, Integrated DNA Technologies, Inc., Cepheid, Inc., and Beckman Coulter, which operates under the Life Sciences and Diagnostics segments. The company provides products
More news about: MarketsandMarkets
Nov 20, 2025, 09:30 ET HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
SSE: 688222.SH), today announced that it has entered into a new contract agreement with the Gates Foundation. HitGen will leverage its industry-leading DNA-encoded library (DEL) platform to identify novel drug leads for the treatment of underserved diseases including tuberculosis and malaria, as well as
More news about: HitGen Inc.
Nov 20, 2025, 09:03 ET THE 2025 SUBARU SHARE THE LOVE® EVENT LAUNCHES WITH HEARTFELT NEW ADVERTISING, TARGETING MORE THAN $350 MILLION IN TOTAL CHARITABLE DONATIONS
Alan Bethke, Senior Vice President of Marketing, Subaru of America, Inc.: "The act of giving back is woven into Subaru's DNA and the daily mission of our incredible charity partners. The Subaru Share the Love Event empowers our owners and retailers to drive lasting change while
More news about: Subaru of America, Inc.
Nov 20, 2025, 09:00 ET Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to
More news about: Co-Diagnostics
Nov 20, 2025, 08:15 ET Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its
More news about: Lucid Diagnostics
Nov 20, 2025, 08:00 ET ALS Network and ALS United Announce New Research Grantees
Noah Zaitlen, PhD; Roel Ophoff, PhD; Martina Wiedau, MD, University of California Los Angeles for Circulating Cell-Free DNA as Biomarker for Amyotrophic Lateral Sclerosis Diagnosis and Disease Progression. Lyandysha Zholudeva,
More news about: ALS Network
Nov 20, 2025, 07:30 ET Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
remain after treatment or surgery to help predict cancer recurrence and guide follow-up decisions OncoExTra Test analyzes DNA and RNA from a patient's tumor to guide therapy for advanced, metastatic, or recurrent solid tumors, delivering actionable insights like targetable mutations,
More news about: Abbott
Nov 20, 2025, 04:00 ET Bairong AI Agents X Leading Chinese Smart Electric Vehicle Automaker |Bairong's New AI Solution
As a representative enterprise in China's smart electric vehicles sector, the car company has always been known for its technological DNA and Internet-native thinking. Since its inception, it has operated like a digital-first company. In marketing, it built a digital
More news about: Bairong Inc.
Nov 19, 2025, 22:51 ET CCTV4: Premiere of Chinese Etiquette & Ceremonies: Understanding China Through the Lens of Li
contribute their perspectives, making this series a true cultural event. This grand exploration of Chinese ritual culture — decoding the behavioral DNA of the Chinese people and celebrating the lasting legacy of Li — begins on the evening of November 21.
More news about: CCTV4
Nov 19, 2025, 22:42 ET CCTV4: Premiere of Chinese Etiquette & Ceremonies: Understanding China Through the Lens of Li
contribute their perspectives, making this series a true cultural event. This grand exploration of Chinese ritual culture — decoding the behavioral DNA of the Chinese people and celebrating the lasting legacy of Li — begins on the evening of November 21.
More news about: CCTV4
Nov 19, 2025, 14:00 ET HEMI® Is Hot; Durango Is Hotter! Dodge Reopens Orders for Durango GT Powered by Pentastar V-6 to Meet Demand
refuse to compromise. Now available with either the Pentastar V-6 or HEMI V-8 power, aggressive styling and room for seven, Durango combines muscle car DNA with SUV practicality — a formula no other competitor offers. The expanding 2026 Dodge Durango lineup includes:
More news about: Stellantis
Nov 19, 2025, 12:00 ET Seen Health's AI-Enabled Model Shows New Impressive Results for Medicaid and Medicare
excellence. "Efficiently scaling this model of deep, personalized care would be impossible without the technology woven into our DNA," said Steve Valderrama, Seen Health's recently appointed Chief Operating Officer. "Our unique operating system provides a single pane of glass to manage
More news about: Seen Health
Nov 19, 2025, 10:10 ET Cell Culture Media Market Outlook: Strong 13.2% CAGR to Drive $12.8 Billion Revenue by 2033 - Grand View Research, Inc.
to drive the market during the forecast period. The COVID-19 pandemic has increased vaccine development activities, especially in the novel mRNA and DNA vaccines space. Vaccine production at a large scale generates a high demand for vectors produced using cell culture techniques.
More news about: Grand View Research, Inc.
Nov 19, 2025, 09:59 ET HKUST Commences Preparations for New Medical School
talent in healthcare and technology for the benefit of both Hong Kong and the nation." "Scientific research is in the HKUST's DNA, and we place paramount importance on interdisciplinary education and research. The HKUST School of Medicine will be guided by the core principle of
More news about: The Hong Kong University of Science and Technology
Nov 19, 2025, 09:51 ET HKUST Commences Preparations for New Medical School
talent in healthcare and technology for the benefit of both Hong Kong and the nation." "Scientific research is in the HKUST's DNA, and we place paramount importance on interdisciplinary education and research. The HKUST School of Medicine will be guided by the core principle of
More news about: The Hong Kong University of Science and Technology
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
comprehensive solutions for research and therapeutic development. With expertise in molecular biology, genetics, and protein science, Tsingke offers custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (AAV, LV, AdV). Its production environments, certified
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
comprehensive solutions for research and therapeutic development. With expertise in molecular biology, genetics, and protein science, Tsingke offers custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (AAV, LV, AdV). Its production environments, certified
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 09:00 ET ToolGen Completes U.S. Patent Registration for Core CRISPR Cas9 RNP Technology; Files U.S. Lawsuit Related to CASGEVY®
via DNA vectors or mRNA, requiring intracellular expression time and raising safety concerns, including off-target editing. ToolGen's patented approach delivers Cas9 directly as a protein complexed with guide RNA (RNP), avoiding DNA/mRNA-related cytotoxicity, eliminating the risk of foreign DNA insertion,
More news about: ToolGen
Nov 19, 2025, 09:00 ET ADVENT ALLEN ENTERTAINMENT AND SIMTEC SYSTEMS TEAM UP TO CREATE THE SPECTACULAR "TOP GUN" THRILL RIDE
innovation and manufacturing excellence to a project of this scale. With our roots in flight simulation, there could be no better fit-it's in our company's DNA. We look forward to fulfilling Top Gun IP's promise of delivering breathtaking, realistic flight action for the first time in an e-ticket attraction,
More news about: Advent Allen Entertainment
Nov 19, 2025, 07:30 ET Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant
More news about: SOLIGENIX, INC.